Global Parkinson’s Disease Therapeutic Market, by Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, and Others), by Route of Administration (Oral, Injectable, Nasal, Transdermal, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,697.3 Mn in 2021 and is expected to exhibit a CAGR of 6.3% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Increasing number of awareness campaigns by non-profit organizations and market players is expected to drive the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in April 2019, ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative drugs for the treatment of central nervous system disorders such as Parkinson’s disease, announced the support of several educational events for the Parkinson's community and their caregivers for the occasion of Parkinson’s awareness month.
Global Parkinson’s Disease Therapeutic Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 virus has spread rapidly and infected millions of people worldwide. In March 2020, the World Health Organization (WHO) announced it as a public health emergency and declared it as a pandemic. Many countries such as the U.S., Germany, France, India, and Japan among others have taken significant steps to combat the COVID-19 epidemic. Parkinson's disease (PD) is the world's second most prevalent neurological illness. Restrictions and problems associated with resource movement have negatively affected patients with Parkinson's disease (PD). Access to PD medication is likely to have been affected negatively by COVID-19 and it resulted in the deterioration of patient’s condition suffering from Parkinson's disease.
COVID-19 reduced the availability of Parkinson's disease treatment in Kenya, Bangladesh, Ghana, and the U.S. Patients with Parkinson's disease suffered from increasing impairment as a result of limited drug access. This has led to increasing clinical PD symptoms in the presence of COVID-19, including motor, non-motor, and neuropsychiatric symptoms. Furthermore, governments' efforts to combat COVID-19 may have reduced the availability of healthcare professionals helping Parkinson's disease patients, which also negatively impacted the Parkinson’s disease therapeutic market.
Browse 32 Market Data Tables and 35 Figures spread through 312 Pages and in-depth TOC on “Global Parkinson’s Disease Therapeutic Market”- Forecast to 2028, Global Parkinson’s Disease Treatment Market, by Drug Class (Levodopa, Dopamine Agonists, MAO-B Inhibitors, Anticholinergics, and Others), by Route of Administration (Oral, Injectable, Nasal, Transdermal and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Parkinson’s Disease Therapeutic Market, click the link below:
Rising product launches by key market players is expected to boost the Parkinson’s disease therapeutic market growth during the forecast period. For instance, Eisai Co., Ltd. announced launch of Equfina 50mg TABLETS (safinamide mesilate, Equfina) for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug containing levodopa. Manufacturing and marketing approval of Equfina were obtained on September 20, 2019 and Equfina was included to Japan’s National Health Insurance Drug Price List on November 19, 2019.
Key Takeaways of the Global Parkinson’s Disease Therapeutic Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.